Improvement of type 2 diabetes in a lung cancer patient treated with Erlotinib.
Costa
Daniel B
DB
Huberman
Mark S
MS
D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000150:complications / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy*; D000069347:Erlotinib Hydrochloride; D005260:Female; D005905:Glyburide / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications / Q000188:drug therapy*; D000077205:Pioglitazone; D011799:Quinazolines / Q000627:therapeutic use*; D045162:Thiazolidinediones / Q000627:therapeutic use
D011799:Quinazolines; D045162:Thiazolidinediones; D000069347:Erlotinib Hydrochloride; D005905:Glyburide; D000077205:Pioglitazone